Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November… Continue reading Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10

Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

Dravet syndrome is a rare, life-long, infant- and childhood-onset epilepsy associated with severe, treatment-resistant seizures CHMP positive opinion based on Phase 3 study data that demonstrated FINTEPLA® significantly reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, including stiripentol Final decision on Marketing Authorization Application expected by year-end 2020… Continue reading Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020

Interim data from open-label extension trial showed substantial seizure reductions were maintained in patients treated with FINTEPLA® for up to two years Post-hoc analysis demonstrated NNTs (Number Needed to Treat) to achieve a clinically meaningful response compared favorably to similar studies of other Dravet syndrome therapies EMERYVILLE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Zogenix,… Continue reading Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020

Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027

EMERYVILLE, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purchasers of the previously announced offering of its 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act… Continue reading Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027

Zogenix Presents New Data at the World Muscle Society Conference 2020

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for Thymidine kinase 2 deficiency (TK2d), at this week’s International Congress of the World Muscle Society (WMS… Continue reading Zogenix Presents New Data at the World Muscle Society Conference 2020

Zogenix Presents New Data at the World Muscle Society Conference 2020

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for Thymidine kinase 2 deficiency (TK2d), at this week’s International Congress of the World Muscle Society (WMS… Continue reading Zogenix Presents New Data at the World Muscle Society Conference 2020

Zogenix Presents New Data at the World Muscle Society Conference 2020

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for Thymidine kinase 2 deficiency (TK2d), at this week’s International Congress of the World Muscle Society (WMS… Continue reading Zogenix Presents New Data at the World Muscle Society Conference 2020

Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities… Continue reading Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering

Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering

EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended… Continue reading Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering

Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering

EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended… Continue reading Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering